Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > India's Gland Pharma posts quarterly profit rise on Cenexi recovery, Europe sales growth
    Finance

    India's Gland Pharma posts quarterly profit rise on Cenexi recovery, Europe sales growth

    India's Gland Pharma posts quarterly profit rise on Cenexi recovery, Europe sales growth

    Published by Global Banking and Finance Review

    Posted on August 5, 2025

    Featured image for article about Finance

    (Reuters) -India's Gland Pharma reported a nearly 50% jump in first-quarter profit on Tuesday, driven by better margins and a recovery at its European unit Cenexi.

    The company reported a consolidated net profit of 2.15 billion rupees ($24.50 million) for the quarter ended June 30, from 1.44 billion rupees in the year-ago quarter.

    Revenue from operations rose 7.4% to 15.06 billion rupees. While sales from its U.S. business, which accounts for nearly half of the total, fell 2%, its Europe business posted a 29% rise.

    For further results highlights, click [FWN3TX07W]

    KEY CONTEXT

    Gland and several Indian pharma companies that make generic drugs derive a significant share of revenue from the United States and has continued to face pricing pressure in that market following U.S. President Donald Trump's imposition of hefty tariffs on goods imported from India.

    Rivals Sun Pharma and Cipla and Dr Reddy's reported subdued U.S. sales in the quarter.

    However, Gland Pharma said improved margins and Cenexi's earnings before interest, taxes, depreciation, and amortisation (EBITDA) break-even supported quarterly performance, marking a turnaround after production setbacks at its Paris and Belgium units weighed on earnings over the past year.

    The company’s EBITDA margin rose to 35% in the June quarter from 29% a year earlier.

    PEER COMPARISON

    Estimates (next Analysts' sentiment

    12 months)

    RIC PE EV/EBI Revenue Profit Mean # of Stock to Div

    TDA growth growth rating* analysts price yield

    (%) (%) target** (%)

    Gland Pharma Ltd 32.17 17.87 12.86 31.29 Hold 11 1.18 0.91

    Alembic 24.49 15.10 10.91 25.76 Buy 10 0.96 1.15

    Pharmaceuticals

    Ltd

    Zydus Lifesciences 21.39 13.94 6.74 -5.10 Hold 26 0.96 1.16

    Ltd

    Cipla Ltd 23.92 15.31 6.65 -0.82 Buy 35 0.89 0.87

    * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

    APRIL TO JUNE STOCK PERFORMANCE

    -- All data from LSEG

    -- $1 = 87.7570 Indian rupeesthe

    (Reporting by Kashish Tandon in Bengaluru)

    Related Posts
    Shell mergers chief Greg Gut quits after CEO blocks bid for BP, FT reports
    Shell mergers chief Greg Gut quits after CEO blocks bid for BP, FT reports
    Exclusive-Britain examines revamp of capital rules for likes of Citadel and XTX
    Exclusive-Britain examines revamp of capital rules for likes of Citadel and XTX
    Oil slips on Russia-Ukraine peace deal talks, weak China data
    Oil slips on Russia-Ukraine peace deal talks, weak China data
    Stocks slide as investors on edge ahead of data, central bank meetings
    Stocks slide as investors on edge ahead of data, central bank meetings
    Human‑wave attacks and drones: How Myanmar's junta is fighting back
    Human‑wave attacks and drones: How Myanmar's junta is fighting back
    When Banking Delays Cross the Line: Legal Rights Around Held Checks
    When Banking Delays Cross the Line: Legal Rights Around Held Checks
    EU to relent on combustion engines ban after auto industry pressure
    EU to relent on combustion engines ban after auto industry pressure
    Dollar on defensive as traders eye delayed US jobs data
    Dollar on defensive as traders eye delayed US jobs data
    US suspends technology deal with Britain, FT reports
    US suspends technology deal with Britain, FT reports
    QuantumDiamonds announces 152 million euros investment plan for new Munich site
    QuantumDiamonds announces 152 million euros investment plan for new Munich site
    British regulator kicks off consultation on new crypto rules
    British regulator kicks off consultation on new crypto rules
    Trump sues the BBC for defamation over editing of January 6 speech, seeks up to $10 billion in damages
    Trump sues the BBC for defamation over editing of January 6 speech, seeks up to $10 billion in damages

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    More from Finance

    Explore more articles in the Finance category

    Europe to launch international commission for Ukraine war damages

    Europe to launch international commission for Ukraine war damages

    South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

    South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

    Uniper to launch sale of 20% stake in Opal gas pipeline

    Uniper to launch sale of 20% stake in Opal gas pipeline

    Trading Day: Payrolls, Fed jitters mount

    Trading Day: Payrolls, Fed jitters mount

    'Battlefield' maker EA forecasts softer 2026 bookings amid slow spending, crowded holiday slate

    'Battlefield' maker EA forecasts softer 2026 bookings amid slow spending, crowded holiday slate

    Britain clinches upgraded South Korea trade deal

    Britain clinches upgraded South Korea trade deal

    Trump says lawsuit against BBC likely to be filed soon

    Trump says lawsuit against BBC likely to be filed soon

    Tesla shares jump as Musk confirms driverless robotaxi testing

    Tesla shares jump as Musk confirms driverless robotaxi testing

    Italy's competition authority drops probe into Eni's Plenitude unit

    Italy's competition authority drops probe into Eni's Plenitude unit

    Bridgewater warns Big Tech's reliance on external capital to fund AI boom is 'dangerous'

    Bridgewater warns Big Tech's reliance on external capital to fund AI boom is 'dangerous'

    Italian firms using AI double in a year but still small minority

    Italian firms using AI double in a year but still small minority

    Juventus shares soar 19% after Agnelli family rejects crypto firm Tether's bid

    Juventus shares soar 19% after Agnelli family rejects crypto firm Tether's bid

    View All Finance Posts
    Previous Finance PostRussia says it has 'no restrictions' now on intermediate-range missile deployment
    Next Finance PostItalian construction group Buzzi lowers 2025 guidance